INVESTIGATION OF HOT MELT EXTRUSION TECHNIQUE FOR FORMULATING TERNARY AMORPHOUS SOLID DISPERSION OF BCS-IV ANTI-PLATELET DRUG FOR SOLUBILITY AND DISSOLUTION ENHANCEMENT

RAJESH GIRADKAR; JANAKI DEVI SIRISOLLA

doi:10.22159/ijap.2025v17i2.52186

Authors

RAJESH GIRADKAR GITAM School of Pharmacy, GITAM Deemed to be University, Rushikonda, Visakhapatnam, A. P, India https://orcid.org/0009-0000-7712-8203
JANAKI DEVI SIRISOLLA GITAM School of Pharmacy, GITAM Deemed to be University, Rushikonda, Visakhapatnam, A. P, India https://orcid.org/0000-0002-6181-8899

DOI:

https://doi.org/10.22159/ijap.2025v17i2.52186

Keywords:

Ternary amorphous solid dispersion, Hot melt extrusion, Dissolution enhancement, Design of experiments

Abstract

Objective: The objective of this study was to investigate Hot Melt Extrusion (HME) technique of formulating stable amorphous solid dispersion of BCS IV drug ticagrelor for dissolution and bioavailability enhancement.

Methods: Ticagrelor, a low soluble and low permeable anti-platelet agent has been used as a model drug. A ternary Amorphous Solid Dispersion (ASD) was explored to improve the solubility and dissolution of ticagrelor using amphiphilic polymer Hydroxy Propyl Methyl Cellulose Acetate Succinate (HMPC-AS) and solubilizer poloxamer (Kolliphor RH188) employing HME. The ratio of ternary ASD was optimized by Design of Experiments (DoE) with 3²-factor design. The Design Expert^®13 was explored for the statistical evaluation.

The HME technique was preferred considering solvent free process, scalability and industrial safety. The extent of amorphization of ticagrelor was evaluated by Differential Scanning Calorimetry (DSC) and Powder X-Ray Diffraction (P-XRD). The comparative saturation solubility was evaluated by HPLC method and drug dissolution rate by UV spectroscopy.

Results: The ternary ASD prepared by HME technique has shown complete amorphization of input crystalline ticagrelor as confirmed by P-XRD and DSC analysis of ticagrelor solid dispersion formulated with HPMC-AS and poloxamer. The ternary ASD formulation was optimized by DoE has shown significant enhancement in ticagrelor solubility and 8 fold increase in dissolution rate and extent compared to conventional release marketed tablets.

Conclusion: A stable tablets formulation of ticagrelor ternary ASD was successfully prepared by HME technique and could enhance in vitro dissolution significantly, to an extent of 8 fold by complete conversion from crystalline to amorphous state.

References

Kansara H, Panola R, Mishra A. Techniques used to enhance bioavailability of BCS class II drugs: a review. Int J Drug Dev Res. 2015;7(1):82-93.

Leuner C, Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm. 2000;50(1):47-60. doi: 10.1016/s0939-6411(00)00076-x, PMID 10840192.

Food and Drug Administration. Drug approval package: brilinta (ticagrelor) NDA #022433. Available online: https://www.accessdata.fda.gov/drugsatfda_ docs/nda/2011/022433orig1s000toc.cfm. [Last accessed 17 Jul 2023].

He Y, Ho C. Amorphous solid dispersions: utilization and challenges in drug discovery and development. J Pharm Sci. 2015;104(10):3237-58. doi: 10.1002/jps.24541, PMID 26175316.

Guo Y, Luo J, Tan S, Otieno BO, Zhang Z. The applications of vitamin E TPGS in drug delivery. Eur J Pharm Sci. 2013;49(2):175-86. doi: 10.1016/j.ejps.2013.02.006, PMID 23485439.

Guzman H, Tawa M, Zhang Z, Ratanabanangkoon P, Shaw P, Mustonen P. A “spring and parachute” approach to designing solid celecoxib formulations having enhanced oral absorption. AAPS J. 2004;6:T2189.

Yadav M, Sarolia J, Vyas B, Lalan M, Mangrulkar S, Shah P. Amalgamation of solid dispersion and melt adsorption technique: improved in vitro and in vivo performance of ticagrelor tablets. AAPS PharmSciTech. 2021;22(8):257. doi: 10.1208/s12249-021-02138-z, PMID 34676463.

Kim SJ, Lee HK, Na YG, Bang KH, Lee HJ, Wang M. A novel composition of ticagrelor by solid dispersion technique for increasing solubility and intestinal permeability. Int J Pharm. 2019;555:11-8. doi: 10.1016/j.ijpharm.2018.11.038, PMID 30448313.

Ghebremeskel AN, Vemavarapu C, Lodaya M. Use of surfactants as plasticizers in preparing solid dispersions of poorly soluble API: selection of polymer-surfactant combinations using solubility parameters and testing the processability. Int J Pharm. 2007;328(2):119-29. doi: 10.1016/j.ijpharm.2006.08.010, PMID 16968659.

Vasconcelos T, Sarmento B, Costa P. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discov Today. 2007;12(23-24):1068-75. doi: 10.1016/j.drudis.2007.09.005, PMID 18061887.

Jamal M, El J, Azza A, Gazy A. Analysis of three cardiovascular drugs in their ternary mixture using green analytical methodology of smart spectrophotometric methods and RP-HPLC method. Int J Pharm Pharm Sci. 2016;8(8):243-50.

Panda R, Lankalapalli S. Design of experiments and optimization of amorphous solid dispersion of a BCS Class IV anti-platelet drug through factorial design. Int J App Pharm. 2023;15(6):353-64. doi: 10.22159/ijap.2023v15i6.48767.

Bueno LM, Manoel JW, Giordani CF, Mendez AS, Volpato NM, Schapoval EE. HPLC method for simultaneous analysis of ticagrelor and its organic impurities and identification of two major photodegradation products. Eur J Pharm Sci. 2017;97:22-9. doi: 10.1016/j.ejps.2016.11.004, PMID 27816632.

Dissolution Methods Database. United States Food and Drug Administration. Available from: http://www.accessdata.fda.gov/scripts/cder/dissolution/index.cfm. [Last accessed on 17 Jun 2023].

Vojinovic T, Medarevic D, Vranic E, Potpara Z, Krstic M, Djuris J. Development of ternary solid dispersions with hydrophilic polymer and surface adsorbent for improving dissolution rate of carbamazepine. Saudi Pharm J. 2018;26(5):725-32. doi: 10.1016/j.jsps.2018.02.017, PMID 29991917.

Gupta MK, Tseng YC, Goldman D, Bogner RH. Hydrogen bonding with adsorbent during storage governs drug dissolution from solid-dispersion granules. Pharm Res. 2002;19(11):1663-72. doi: 10.1023/a:1020905412654, PMID 12458672.

Chokshi RJ, Zia H, Sandhu HK, Shah NH, Malick WA. Improving the dissolution rate of poorly water soluble drug by solid dispersion and solid solution: pros and cons. Drug Deliv. 2007;14(1):33-45. doi: 10.1080/10717540600640278, PMID 17107929.

Chiou WL, Riegelman S. Pharmaceutical applications of solid dispersion systems. J Pharm Sci. 1971;60(9):1281-302. doi: 10.1002/jps.2600600902, PMID 4935981.

Tambosi G, Coelho PF, Luciano S, Lenschow IC, Zétola M, Stulzer HK. Challenges to improve the biopharmaceutical properties of poorly water-soluble drugs and the application of the solid dispersion technology. Materia (Rio J). 2018;23(4). doi: 10.1590/s1517-707620180004.0558.

Tan DK, Davis DA, Miller DA, Williams RO, Nokhodchi A. Innovations in thermal processing: hot-melt extrusion and KinetiSol® dispersing. AAPS PharmSciTech. 2020;21(8):312. doi: 10.1208/s12249-020-01854-2, PMID 33161479.

Kala SG, Chinni S. Development and characterization of venetoclax nanocrystals for oral bioavailability enhancement. AAPS PharmSciTech. 2021;22(3):92. doi: 10.1208/s12249-021-01968-1, PMID 33683477.

Farooqui P, Gude R. Formulation development and optimisation of fast dissolving buccal films loaded glimepiride solid dispersion with enhanced dissolution profile using central composite design. Int J Pharm Pharm Sci. 2023;15(6):35-54. doi: 10.22159/ijpps.2023v15i6.47992.